Igyxos Biotherapeutics is focused on revolutionizing infertility treatment through the development of innovative monoclonal antibody (mAb) therapeutics, specifically targeting the enhancement of gonadotropins, which are crucial hormones for reproduction. Their lead product, IGX12, is designed to boost the bioactivity of Follicle Stimulating Hormone (FSH), a key hormone that plays a vital role in the development of eggs in women and sperm in men. By improving FSH receptor binding and activity, Igyxos aims to address the limitations of current infertility treatments, potentially leading to higher success rates and better patient outcomes.

The scientific foundation of Igyxos' approach lies in the unique mechanism of action of IGX12, which involves binding to both the alpha and beta subunits of FSH, stabilizing the hormone's dimeric form. This interaction enhances the hormone's ability to activate its receptor, thereby improving its efficacy in stimulating reproductive processes. The company has validated its approach through in vivo models, indicating that IGX12 could provide a more effective treatment option for infertility in both men and women, either as a standalone therapy or in conjunction with existing gonadotropin treatments.

France

Igyxos Biotherapeutics, a French biotechnology company, is dedicated to addressing the growing global need for improved infertility solutions through novel therapeutics that make treatment more effective and efficient for men and women. To transform infertility treatment and enhance patients’ outcomes, we’re pioneering the first monoclonal antibody (mAb)-based treatment that binds to and enhances the activity of gonadotropins – hormones involved in reproduction – and significantly improves their activity for infertility treatments.

Igyxos Biotherapeutics

Company Details